HC100© Infusion
HC100© is an exclusive infusion technology device which improves the quality of life for those patients receiving infusions of vesicant and irritant drugs such as chemotherapeutics. HC100 permits a safe and cost convenient infusion therapy which reduces risks and injuries to all patients in need of vesicant and irritant drugs infusions.
Intellectual PropertyPatents Granted.CE certified #1715/MDD IMQ 01/10/2014.
Vascular damage
Vascular damage induced by ions and cytotoxic drugs are frequent events and known as chemical phlebitis. Swissmedendi’s infusion technology device HC100© assist in the prevention of:• Loss of endothelial cells• Inflammatory cells infiltration• Edema• Thrombosis• Sclerosis
Injuries can be proximal or distal to the catheter tips and usually irritates the venousendothelial cells over a longer distance from the catheter tip.
Unique Methods and Technology
Swissmedendi owns unique technology able to protect patients’ veins from vesicant agents causing irreversible endothelial damage; saving lives and reducing risks and injuries to patients and offering enormous cost saving.
All our devices are disposable non invasive class IIa (Europe) and class 2 (USA). These do not vary therapeutics administration protocols, infusion speed or drug concentration.Employing the technology will help hospitals to manage costs, enable doctors to focus more on their patients’ needs, and improve patients’ quality of life.The devices are easy to use and adaptable to devices currently in use.
